dailyfinance.com 2010-04-13 For investors on the hunt for groundbreaking technologies, stem cell therapies originally looked promising. But the world has been waiting for a long time for the basic research to transform into viable therapies, and in the meantime, Wall Street has largely lost interest. Now, however, there’s a “disconnect between science and valuation in [...]